The Fundación La Caixa has earmarked €32.4 million for 80 biomedical research and innovation projects, Europa Press reported on Thursday, October 15, 2026.
The funding falls under the foundation's 2026 research and innovation grants, according to Europa Press. Among the supported efforts are a drug targeting a rare form of cancer and a DNA-based vaccine aimed at a drug-resistant "superbug," El Periódico reported.
The Cima Universidad de Navarra will receive more than €1.5 million for five of its research projects, according to Navarra.com and Diario de Navarra. Separately, a project focused on improving control of strongyloidiasis — a parasitic infection — was awarded one of the 2026 CaixaImpulse Innovation grants, the URV's digital news outlet reported.
The grants span multiple institutions and research areas, reflecting the foundation's stated aim of backing both basic biomedical science and innovation-oriented work. The awards cover projects selected across Spain, with recipients ranging from university research centers to individual investigators.
The scale of the commitment — 80 projects sharing €32.4 million — places it among the foundation's larger annual research funding rounds. The specific project titles, lead researchers, and individual grant amounts beyond those reported have not been detailed in the available coverage.
Further details on the selected projects and how the funding will be distributed are expected as the foundation and recipient institutions release additional information.
